Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8403MR)

This product GTTS-WQ8403MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8403MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13767MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ7963MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ2476MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 181
GTTS-WQ218MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 13C5.5
GTTS-WQ2847MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG-570
GTTS-WQ2695MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ8213MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ8973MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ILV-094
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW